Search
GS030-DP
go.drugbank.com/drugs/DB17847InvestigationalIt targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector.
Ty800
go.drugbank.com/drugs/DB04989InvestigationalIt is being developed by AVANT Immunotherapeutics, Inc.
AC-003
go.drugbank.com/drugs/DB22691Investigational[L53458,L53463] By inhibiting RIPK1 kinase activity, AC-003 thereby inhibits RIPK1-mediated cell death and inflammation.
Perphenazine
go.drugbank.com/drugs/DB00850ApprovedInvestigationalAn antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Clobetasone
go.drugbank.com/drugs/DB13158ApprovedClobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions. Topical clobetasone butyr...
Products: U-CLOSONE CREAM, U-CLOSONE OINTMENTSulfamethazine
go.drugbank.com/drugs/DB01582ApprovedVet approvedWithdrawnA sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.
Anthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalAnthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax. It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified. Available as the...
Perhexiline
go.drugbank.com/drugs/DB01074ApprovedPerhexiline is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.
Minocycline
go.drugbank.com/drugs/DB01017ApprovedInvestigationalMinocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifi...
Talniflumate
go.drugbank.com/drugs/DB09295InvestigationalPhase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this